fda and compounding tirzepatide ban on compounded tirzepatide: Switch to name brand medications Is Tirzepatide Legal in 2026?

Description

For patients with recurrent vulvovaginal candidiasis (four or more episodes annually), management should include: Microscopy and culture to identify the Candida species An induction-maintenance regimen (e.g., fluconazole 150mg every 72 hours for three doses, followed by weekly maintenance for up to six months) Thorough review of predisposing factors Management strategies for patients on Ozempic should include: Optimising glycaemic control as the cornerstone of preventionreviewing HbA1c targets and adjusting diabetes medications as needed Completing the full course of antifungal treatment even if symptoms resolve early Treating sexual partners if they have symptoms (though routine partner treatment is not necessary for uncomplicated cases) Reviewing and addressing modifiable risk factors Considering prophylactic antifungal therapy for patients with frequent recurrences Patients should be reassured that yeast infections, whilst uncomfortable, are treatable and that continuing Ozempic is appropriate provided diabetes control is optimised

S.DubreuilM.AndrewsJ

Start your journey today by taking our free eligibility quiz.

Tier Product description Product Specifications Active Compound: Retatrutide peptide Strength: 30mg per vial Form: Lyophilized powder Reconstitution Required: Yes, according to a validated laboratory protocol Manufacturer, as listed: Novera Compounds Country of Origin, as listed: United States Brand: Novera Intended Use: Laboratory and in vitro research only Package Content: 1 x 30mg vial Weight: 7 grams Dimensions: Width: 20mm | Height: 40mm | Length: 20mm Human-Use Status: Not approved for human use, clinical application, injection, or consumption What Is Retatrutide 30mg